Almac Clinical Technologies’ response to Coronavirus (COVID-19) Outbreak

Home /

Upon declaration by the World Health Organisation (WHO) of this situation in late January, Almac Clinical Technologies enacted its Business Continuity Plan, which ensures the health and well being of personnel, the minimisation of risk to business operations, as well as management of resources, to ensure our capacities and service levels are maintained for clients.

Almac’s global facilities have remained open and operational. The effectiveness of our Business Continuity Plan (BCP) processes has been continually monitored (and adjusted) to minimise any potential impact this pandemic would have to our worldwide operations. To date, Almac Clinical Technologies has not experienced any significant operational impact due to the Coronavirus outbreak and our service levels remain unchanged.

Almac Clinical Technologies’ Continual Monitoring of the Situation

  • Daily assessment of the global situation is occurring to establish the impact on business activities.
  • A “Silver Command” teams consisting of Sr. Directors/Managers/Executives have been established at our European, Asia Pacific and North American facilities. Silver Command will meet frequently to proactively develop contingencies for any suspected transmissions of the virus and/or business impact at any of our facilities.
  • Almac Clinical Technologies has implemented Continuity Planning to sustain business operations and minimize any potential impacts. Due to the nature of Almac Clinical Technologies work, the vast majority of employees have access to all the necessary tools and resources while working from home and where employees don’t, alternative arrangements are being made. If needed we will institute an enhanced telecommuting arrangement with employees, with the expectation that business should continue as normal, and during normal business hours.   Additionally, while none of our Almac employees have contracted the virus, should a breakout occur in an Almac office or region, we have agreed suitable contingency plans to ensure you will not experience any service interruption.

Supply Chain Considerations

Almac Clinical Technologies would like to encourage you to actively consider the following proactive measures to safeguard against disruptions in the supply chain:

  • Consider increasing site stock levels where possible, through increased drug order quantities.
  • We would encourage you to consider an extension to projection windows or site stock in areas considered to be exposed to imminent risk of disruption.
  • Review any planned/scheduled import activities to impacted areas.
  • Consider the timing for the initiation of any new patients, sites and clinical studies to impacted areas.
  • Consider the option to register patient visits in different sites if the originating site is closed (i.e. move the patient to an open site).

We recommend that you assess the effect of these measures along with any wider public/private closures upon your clinical sites and clinical studies. Almac will continue to monitor the impact of these changing situations and will provide updated advice as it becomes available.

Should you have any additional concerns regarding your specific project, please do not hesitate to contact your Almac representative.

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies